Delivery of anti-angiogenic molecular therapies for retinal disease.
Angiogenic diseases of the retina are the leading cause of blindness in the developed world. The development of anti-angiogenic molecular therapies has transformed the prognosis of these conditions, especially age-related macular degeneration. With these new treatments comes the new challenge of delivering an effective dosage to the retina, over a prolonged period of time and in a safe and cost-effective manner. A range of new anti-angiogenics are on the horizon, offering new and varied modes of drug delivery. In addition, a range of new sustained-release drug delivery technologies are being developed.
Anderson
Owen A
OA
UCL Institute of Ophthalmology, 11-43 Bath Street, London EC1V9EL, United Kingdom. o.anderson@ucl.ac.uk
Bainbridge
James W B
JW
Shima
David T
DT
D020341:Absorbable Implants; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use*; D000818:Animals; D016503:Drug Delivery Systems; D004343:Drug Implants; D015316:Genetic Therapy; D006801:Humans; D007267:Injections; D012164:Retinal Diseases / Q000188:drug therapy*; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D004343:Drug Implants